1st Quarter - Report

CALIFORNIA LIFE SCIENCES for CALIFORNIA LIFE SCIENCES

Firm
Client
Income
—
Expenses
$130,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Support repeal of medical device tax.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
ADAM LOTSPIKE —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Budget/Appropriations BUD

Labor/HHS/Ed Appropriations: NIH, biodefense/pandemic, science/math education, and strategic stockpile funding and preparation; FDA Appropriations; PTO Appropriations.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
ADAM LOTSPIKE —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE

Medical/Disease Research/Clinical Labs MED

Support NIH research funding. Support implementation of 21st Century Cures Act.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
ADAM LOTSPIKE —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Copyright/Patent/Trademark CPT

Address concerns with provisions of patent litigation reform, including inter partes review. Support STRONGER Patents Act. Educate on Bayh-Dole Act "march-in" provision.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
ADAM LOTSPIKE —

Contacted: SENATE; Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Health Issues HCR

Support FDA user fee programs and review process consistency and predictability. Support PAHPA re- authorization.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
ADAM LOTSPIKE —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE

Medicare/Medicaid MMM

Support repeal of Medicare Independent Payment Advisory Board (IPAB). Address concerns with changes to Medicare Part B and Part D programs, and Hospital Outpatient Prospective Payment System. Support Advancing Access to Precision Medicine Act. Oppose changes to Medicare Advantage and Part D prescription drug benefit. Support creation of improved payment pathway for novel and breakthrough medical devices.

LobbyistCovered position, as disclosed
JENNIFER NIETO CAREY —
ADAM LOTSPIKE —

Contacted: Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.